Issue link: https://www.e-digitaleditions.com/i/1496325
Inhalation April 2023 33 Inhaled and nasal drug delivery systems RxPack is a global leader in pharmaceutical dispens- ing solutions and inhaled and nasal drug delivery sys- tems. Specializing in pMDIs, it offers valves suitable for solution and suspension formulations, single- and double-stage filling and combination or single for- mulations. Low moisture ingress and fast filling are among key features. Valves and actuators are avail- able for HFA 134a and green gasses. RxPack can also guide customers from R&D to full-scale manufac- turing. For pMDI filling equipment, RxPack works in partnership with Coster, which manufactures lab- scale machines and high-speed lines. RxPack S.r.l. Italy: +39 0341 18960 info@rxpack.it www.rxpack.eu Dry powder inhalation capsule portfolio Lonza's Capsugel ® Zephyr™ dry powder inhalation (DPI) capsule portfolio is a comprehensive capsule product offering, featuring customized DPI capsules and dedicated equipment in place for efficient, phase- appropriate capsule filling. e Zephyr DPI portfolio addresses the need for highly customized solutions for pulmonary route delivery methods and is supported by Lonza's inhalation and drug development and par- ticle engineering capabilities. is integrated product and service offering enables consistent and optimal release performance for inhalation drugs. Lonza Capsules & Health Ingredients US: +1 888 783-6361 www.capsugel.com Single service or comprehensive development Catalent Inhalation has the capabilities, expertise and state-of-the-art facilities to expedite product development, from concept and feasibility studies through commercial manufacture and release testing. Whether a single service or a comprehensive develop- ment package is required, Catalent offers end-to-end inhalation expertise across dry powder inhaler (DPI) and unit and bi-dose nasal spray dose forms. Catalent also provides integrated analytical, particle size engi- neering and clinical trial supply services. Catalent US: + 1 888 SOLUTION (765-8846) www.catalent.com Independent delivery technology selection ere are several approaches to consider when initi- ating the development of a new inhalation product. Formulations can be aqueous, powder or propel- lant-based in nature, and different technologies can be used to generate each of these. Finding the right for- mulation platform then pairing it with an appropriate device is critical to the success of an inhalation proj- ect. Intertek is not tied to proprietary device or for- mulation platforms, meaning we can independently consider all approaches to find the best solution for our clients. Intertek Pharmaceutical Services UK: +44 1763 261648 bd.melbourn@intertek.com www.intertek.com